1989 related articles for article (PubMed ID: 18280761)
41. Inhaled corticosteroids in COPD: a controversy.
Barnes PJ
Respiration; 2010; 80(2):89-95. PubMed ID: 20501985
[TBL] [Abstract][Full Text] [Related]
42. Recent advances in COPD disease management with fixed-dose long-acting combination therapies.
Bateman ED; Mahler DA; Vogelmeier CF; Wedzicha JA; Patalano F; Banerji D
Expert Rev Respir Med; 2014 Jun; 8(3):357-79. PubMed ID: 24802656
[TBL] [Abstract][Full Text] [Related]
43. [Inhaled corticosteroids in patients with COPD: maintain current guidelines].
Heijdra YF
Ned Tijdschr Geneeskd; 2007 Oct; 151(40):2195-7. PubMed ID: 17969568
[TBL] [Abstract][Full Text] [Related]
44. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
[TBL] [Abstract][Full Text] [Related]
45. Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization.
Gagnon YM; Levy AR; Spencer MD; Hurley JS; Frost FJ; Mapel DW; Briggs AH
Respir Med; 2005 Dec; 99(12):1534-45. PubMed ID: 16291076
[TBL] [Abstract][Full Text] [Related]
46. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
47. Combination long-acting β-agonists and inhaled corticosteroids compared with long-acting β-agonists alone in older adults with chronic obstructive pulmonary disease.
Gershon AS; Campitelli MA; Croxford R; Stanbrook MB; To T; Upshur R; Stephenson AL; Stukel TA
JAMA; 2014 Sep; 312(11):1114-21. PubMed ID: 25226477
[TBL] [Abstract][Full Text] [Related]
48. Innovations to achieve excellence in COPD diagnosis and treatment in primary care.
Fromer L; Barnes T; Garvey C; Ortiz G; Saver DF; Yawn B
Postgrad Med; 2010 Sep; 122(5):150-64. PubMed ID: 20861599
[TBL] [Abstract][Full Text] [Related]
49. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease.
Sin DD; Man SF; Marciniuk DD; Ford G; FitzGerald M; Wong E; York E; Mainra RR; Ramesh W; Melenka LS; Wilde E; Cowie RL; Williams D; Gan WQ; Rousseau R;
Am J Respir Crit Care Med; 2008 Jun; 177(11):1207-14. PubMed ID: 18310480
[TBL] [Abstract][Full Text] [Related]
50. Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease.
Sin DD; Man SF
Proc Am Thorac Soc; 2006 Sep; 3(7):624-9. PubMed ID: 16963545
[TBL] [Abstract][Full Text] [Related]
51. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD.
Short PM; Williamson PA; Elder DHJ; Lipworth SIW; Schembri S; Lipworth BJ
Chest; 2012 Jan; 141(1):81-86. PubMed ID: 21799028
[TBL] [Abstract][Full Text] [Related]
52. Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting β-agonist for COPD: A Meta-analysis.
Oba Y; Chandran AV; Devasahayam JV
COPD; 2016 Dec; 13(6):677-685. PubMed ID: 27148815
[TBL] [Abstract][Full Text] [Related]
53. Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender.
Tashkin DP; Varghese ST
Pulm Pharmacol Ther; 2011 Feb; 24(1):147-52. PubMed ID: 20659577
[TBL] [Abstract][Full Text] [Related]
54. Survival of COPD patients using inhaled corticosteroids and long-acting beta agonists.
Mapel DW; Hurley JS; Roblin D; Roberts M; Davis KJ; Schreiner R; Frost FJ
Respir Med; 2006 Apr; 100(4):595-609. PubMed ID: 16199151
[TBL] [Abstract][Full Text] [Related]
55. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease.
Lee TA; Wilke C; Joo M; Stroupe KT; Krishnan JA; Schumock GT; Pickard AS
Arch Intern Med; 2009 Aug; 169(15):1403-10. PubMed ID: 19667304
[TBL] [Abstract][Full Text] [Related]
56. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
Calverley P; Pauwels R; Vestbo J; Jones P; Pride N; Gulsvik A; Anderson J; Maden C;
Lancet; 2003 Feb; 361(9356):449-56. PubMed ID: 12583942
[TBL] [Abstract][Full Text] [Related]
57. Chronic obstructive pulmonary disease: Useful medications for patients with recurrent symptoms.
Prescrire Int; 2016 Nov; 25(176):272-277. PubMed ID: 30715829
[TBL] [Abstract][Full Text] [Related]
58. Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis.
Tricco AC; Strifler L; Veroniki AA; Yazdi F; Khan PA; Scott A; Ng C; Antony J; Mrklas K; D'Souza J; Cardoso R; Straus SE
BMJ Open; 2015 Oct; 5(10):e009183. PubMed ID: 26503392
[TBL] [Abstract][Full Text] [Related]
59. Comparisons of Efficacy and Safety between Triple (Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting Beta-Agonist) Therapies in Chronic Obstructive Pulmonary Disease: Systematic Review and Bayesian Network Meta-Analysis.
Lee HW; Kim HJ; Jang EJ; Lee CH
Respiration; 2021; 100(7):631-643. PubMed ID: 33971649
[TBL] [Abstract][Full Text] [Related]
60. Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit?
Man SF; Sin DD
Drugs; 2005; 65(5):579-91. PubMed ID: 15748094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
